Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
136. |
ECCT/22/06/02 | Mitapivat - AG348-C-020 A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. |
Principal Investigator(s) 1. Lucas Otieno Tina 2. Bernhards Ragama Ogutu 3. Prof Jessie N Githanga 4. Videlis N Nduba 5. Janet N/A Oyieko 6. Allan Godfrey Otieno Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. Strathmore University Medical Centre (Nairobi City county) 3. KEMRI/CRDR (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) 5. Gertrude’s Children’s Hospital (Nairobi City county) 6. KEMRI Kondele Children\'s Hospital (Kisumu county) 7. Kombewa Clinical Research Centre (Kisumu county) |
View |
137. |
ECCT/22/06/01 | The INSIGHT cohort A cohort for evaluation of open-label PrEP delivery and PrEP preferences among African women |
Principal Investigator(s) 1. Elizabeth Anne Bukusi Site(s) in Kenya KEMRI RCTP, LUMUMBA SUBCOUNTY HOSPITAL |
View |
138. |
ECCT/22/05/03 | Anti-malaria MAb in Kenyan chi Safety and Efficacy of L9LS, a Human Monoclonal Antibody Against Plasmodium falciparum, in an Age De-Escalation, Dose-Escalation Trial and a Randomized, Placebo-Controlled, Double-Blind Trial of Children in Western Kenya |
Principal Investigator(s) 1. Titus Kwambai 2. Laura Steinhardt 3. Robert A Seder Site(s) in Kenya 1. Siaya County Referral Hospital (Siaya county) 2. Kogelo Health Center (Siaya county) |
View |
139. |
ECCT/22/05/02 | BREATHER Plus A randomised open-label 2-arm, 96-week trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily dolutegravir/tenofovir-based triple ART in virologically suppressed HIV-infected adolescents aged 12 to 19 years of age in sub-Saharan Africa |
Principal Investigator(s) 1. Abraham Siika Site(s) in Kenya Moi University Clinical Research Centre |
View |
140. |
ECCT/22/05/01 | VICTORION-2 PREVENT A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease |
Principal Investigator(s) 1. Anthony Gikonyo 2. ELIJAH SAMMY NYAINDA OGOLA Site(s) in Kenya 1. The Karen Hospital (Nairobi City county) 2. Centre for research in Therapeutic Sciences (CREATES (Nairobi City county) |
View |